Article

Characterising the benefits and risks of vaccines approved through accelerated pathways

2025-06-01

Abstract excerpt

Alternative regulatory pathways for vaccine licensure without traditional Phase III efficacy trials are of increasing priority for epidemic pathogens. Using IXCHIQ, a chikungunya virus vaccine licensed through an accelerated pathway, we demonstrate that prior understanding of disease risk from infection can inform risk-benefit assessments for new vaccines. The mass deployment of IXCHIQ during an ongoing outbreak i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 71a8a713-77db-55af-bb36-bd600b912e5d
DOI: 10.1101/2025.05.31.25328649

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Characterising the benefits and risks of vaccines approved through accelerated pathwaysDOI 10.1101/2025.05.31.25328649Read

Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventionsSemantic proximity Read

The Safety and Efficacy of the Chikungunya Virus Vaccine: A Systematic Review and Meta Analysis.Semantic proximity Read

Reanalysis of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine data fails to find any increased efficacy following the boost: Implications for vaccination policy and our understanding of the mode of actionSemantic proximity Read

Programmatic considerations for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: stakeholder analysisSemantic proximity Read

Vaccine-enhanced disease: case studies and ethical implications for research and public healthSemantic proximity Read

The Yellow Fever Vaccine Journey: Milestones and Future DirectionsSemantic proximity Read

Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQ®)Semantic proximity Read

Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studySemantic proximity Read

Challenges, Progress, and Pathways to Equitable ACCESS in Lassa Fever Vaccine DevelopmentSemantic proximity Read

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platformSemantic proximity Read

100 Day Vaccine Development–An Alternative Approach Boosters for Phase III Trialed Viral Family VaccinesSemantic proximity Read

The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differencesSemantic proximity Read